AI Score

Unlock

Tonix Pharmaceuticals Hol... (TNXP)

AI Score

Unlock

26.51

-2.25 (-7.82%)

At close: Mar 27, 2025, 3:59 PM

-7.82% (1D)

Bid	26.25
Market Cap	170.59M
Revenue (ttm)	2.87B
Net Income (ttm)	-36.97B
EPS (ttm)	-176.6
PE Ratio (ttm)	-0.15
Forward PE	-0.02
Analyst	Strong Buy

Ask	27.5
Volume	1,085,758
Avg. Volume (20D)	1,666,013
Open	28.94
Previous Close	28.76
Day's Range	24.35 - 28.94
52-Week Range	6.76 - 1088.00
Beta	2.24

About TNXP

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, auto...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 10, 2012

Employees 81

Stock Exchange NASDAQ

Ticker Symbol TNXP

Website https://www.tonixpharma.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for TNXP stock is "Strong Buy." The 12-month stock price forecast is $585, which is an increase of 2106.71% from the latest price.

Stock Forecasts

Earnings Surprise

Tonix Pharmaceuticals has released their quartely earnings on Mar 18, 2025:

Revenue of $2.58M misses estimates by $618K, with -31.68% YoY decline.

EPS of -9.77 exceeds estimates by 758.23, with 99.64% YoY growth.

Next Earnings Release

Tonix Pharmaceuticals Holding Corp. is scheduled to release its earnings on May 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 days ago

+32.48%

Tonix Pharmaceutical shares are trading higher aft... Unlock content with Pro Subscription

1 week ago

-19.78%

Tonix Pharmaceuticals Holdings shares are trading lower after the company reported mixed Q4 financial results.

News

1 day ago · seekingalpha.com

Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years

PDUFA date of August 15th of 2025 set to review on whether or not TNX-102 SL should be approved to treat patients with Fibromyalgia. The company announced that the FDA will not require an Advisory Com...

2 days ago · marketbeat.com

Pharma Frenzy: Volatility Ignites Biotech Sector

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price surges in Tonix Pharmaceuticals NASDAQ: TNXP and Lexeo Therapeutics NASDAQ: LXEO...

1 week ago · accessnewswire.com

As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas the 2022 Clade II mpox - still spreading ...

1 week ago · benzinga.com

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.

2 weeks ago · accessnewswire.com

Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations ...

1 month ago · marketbeat.com

Is Tonix Pharmaceuticals the Next Biotech Breakout?

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals NASDAQ: TNXP is gaining significant attention from investors and market participants. The company develops therapies for conditions with ...